About Sunshine Biopharma, Inc.
https://www.sunshinebiopharma.comSunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs.
CEO
Steve N. Slilaty
Compensation Summary
(Year 2023)
Salary $378,000
Bonus $182,000
Total Compensation $560,000
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Went public February 15, 2022
Method of going public IPO
Full time employees 52
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-08-08 | Reverse | 1:20 |
| 2024-04-17 | Reverse | 1:100 |
Ratings Snapshot
Rating : B
Discounted Cash Flow 4
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 5
Overall Score 3
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $6.72 M
52w High $3.90
52w Low $1.16
P/E 0.23
Volume 11.77K
Outstanding Shares 4.91M
About Sunshine Biopharma, Inc.
https://www.sunshinebiopharma.comSunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $9.42M ▲ | $4.16M ▼ | $-883.82K ▲ | -9.39% ▲ | $-0.19 ▲ | $-925.1K ▲ |
| Q2-2025 | $9.41M ▲ | $5.48M ▲ | $-1.77M ▼ | -18.82% ▼ | $-7.8 ▼ | $-1.91M ▼ |
| Q1-2025 | $8.9M ▼ | $4.03M ▼ | $-1.18M ▲ | -13.26% ▲ | $-0.44 ▲ | $-1.16M ▲ |
| Q4-2024 | $9.6M ▲ | $5.13M ▲ | $-2.16M ▼ | -22.49% ▼ | $-0.84 ▲ | $-2.21M ▼ |
| Q3-2024 | $8.44M | $3.97M | $-1.2M | -14.2% | $-0.94 | $-918K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $9.31M ▼ | $31.49M ▼ | $7.29M ▲ | $24.2M ▼ |
| Q2-2025 | $10.31M ▲ | $31.97M ▲ | $6.28M ▼ | $25.68M ▲ |
| Q1-2025 | $8.2M ▼ | $29.19M ▼ | $6.48M ▼ | $22.7M ▼ |
| Q4-2024 | $9.69M ▼ | $30.56M ▲ | $7.06M ▲ | $23.5M ▼ |
| Q3-2024 | $12.21M | $30.06M | $5.02M | $25.04M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-883.82K ▲ | $-727.8K ▲ | $-118.3K ▲ | $75.54K ▼ | $-998.88K ▼ | $-735.84K ▲ |
| Q2-2025 | $-1.77M ▼ | $-1.27M ▲ | $-491.78K ▼ | $3.61M ▲ | $2.18M ▲ | $-1.82M ▲ |
| Q1-2025 | $-1.18M ▲ | $-1.71M ▲ | $-176.02K ▲ | $338.14K ▼ | $-1.56M ▲ | $-1.93M ▲ |
| Q4-2024 | $-2.16M ▼ | $-3.41M ▼ | $-531.53K ▲ | $2.05M ▲ | $-2.52M ▼ | $-3.85M ▼ |
| Q3-2024 | $-1.2M | $-1.36M | $-578.37K | $1.87M | $698.91K | $-1.88M |
CEO
Steve N. Slilaty
Compensation Summary
(Year 2023)
Salary $378,000
Bonus $182,000
Total Compensation $560,000
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Went public February 15, 2022
Method of going public IPO
Full time employees 52
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-08-08 | Reverse | 1:20 |
| 2024-04-17 | Reverse | 1:100 |
Ratings Snapshot
Rating : B
Discounted Cash Flow 4
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 5
Overall Score 3
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0